BTKwt
Alternative Names: BTK-wtLatest Information Update: 18 Sep 2023
At a glance
- Originator X-Rx
- Class Anti-inflammatories; Small molecules
- Mechanism of Action Agammaglobulinaemia tyrosine kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Inflammation
Most Recent Events
- 18 Sep 2023 Discontinued - Preclinical for Inflammation in USA (unspecified route) (X-Rx pipeline, September 2023)
- 28 Sep 2020 No recent reports of development identified for preclinical development in Inflammation in USA
- 05 Aug 2016 Preclinical trials in Inflammation in USA (unspecified route)